Clinical Trial Update: STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study) [Phase 3]

View source ↗

Summary

The STRADIVARIUS Phase 3 trial evaluating rimonabant for coronary atherosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Atherosclerosis

Drugs mentioned

• Acomplia (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Coronary Atherosclerosis | Phase 3 | Status: COMPLETED